Trial in progress: Multicenter observational study to evaluate the relationship between gut bacterial flora and their therapeutic or adverse effects in advanced non-small cell lung cancer patients treated with nivolumab.

Takashi Yokoi,Ryo Itotani,Maiko Niki,Hiroshige Yoshioka,Katsuya Hirano,Suguru Yamamoto,Hideki Ishikawa,T. Kijima,Masataka Hirabayashi,Motonari Fukui

Trial in progress: Multicenter observational study to evaluate the relationship between gut bacterial flora and their therapeutic or adverse effects in advanced non-small cell lung cancer patients treated with nivolumab.

2018

Takashi Yokoi
Ryo Itotani
Maiko Niki
Hiroshige Yoshioka
Katsuya Hirano
Suguru Yamamoto
Hideki Ishikawa
T. Kijima
Masataka Hirabayashi
Motonari Fukui

TPS9114Background: Nivolumab is one of the standard therapies for pretreated advanced non-small cell lung cancer (NSCLC). A correlation between PD-L1 expression on tumor cells and antitumor effects...

Keywords:

Nivolumab
Observational study
Pathology
Lung cancer
Adverse effect
Medicine
Oncology
non small cell
tumor cells
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations